title: Effects of interleukin-6 blockade on the development of autoimmune thyroiditis in nonobese diabetic mice.
abstract: We explored the role of interleukin-6 (IL-6) in the development of autoimmune thyroiditis in nonobese diabetic (NOD) mice, an animal model of Hashimoto's thyroiditis, using anti-mouse IL-6 receptor antibody (MR16-1). Thyroiditis was induced by iodide ingestion or mouse thyroglobulin (Tg) immunization. Mice were injected intraperitoneally with saline, control rat IgG, or MR16-1 (2 or 8 mg). Iodide ingestion did not increase serum IL-6 levels and MR16-1 (2 mg) failed to prevent the development of thyroiditis. In contrast, Tg immunization induced a rapid and significant increase in serum IL-6 levels. While MR16-1 (2 mg) had no effect on Tg-induced thyroiditis, the severity, but not incidence, of thyroiditis was reduced in 8 mg MR16-1-treated mice compared with saline-injected mice. However, thyroiditis development in the 8 mg MR16-1-treated mice was indistinguishable from that in the control IgG-treated mice. MR16-1 (8 mg) did not affect serum anti-Tg antibody levels. These results suggest that IL-6 may play only a minor role in the development of autoimmune thyroiditis in NOD mice.
authors.affiliation: Tohoku University Graduate School of Medicine, Sendai, Japan. kokimori@mail.tains.tohoku.ac.jp
authors.forename: Kouki
authors.initials: K
authors.lastname: Mori
authors.forename: Katsumi
authors.initials: K
authors.lastname: Yoshida
authors.forename: Masahiko
authors.initials: M
authors.lastname: Mihara
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Ohsugi
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Nakagawa
authors.forename: Saeko
authors.initials: S
authors.lastname: Hoshikawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ozaki
authors.forename: Sadayoshi
authors.initials: S
authors.lastname: Ito
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D003208:Concanavalin A / Q000494:pharmacology; D004195:Disease Models, Animal; D050031:Hashimoto Disease / Q000209:etiology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007132:Immunoglobulin Isotypes / Q000097:blood / Q000276:immunology; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D015850:Interleukin-6 / Q000097:blood / Q000502:physiology*; D007455:Iodine / Q000008:administration & dosage / Q000494:pharmacology; D051379:Mice; D016688:Mice, Inbred NOD; D019947:Receptors, Interleukin-6 / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D013954:Thyroglobulin / Q000276:immunology; D013967:Thyroiditis, Autoimmune / Q000209:etiology* / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D014611:Vaccination; D000093242:Interleukin-6 Inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D003208:Concanavalin A; D007074:Immunoglobulin G; D007132:Immunoglobulin Isotypes; D007371:Interferon-gamma; D016753:Interleukin-10; D015850:Interleukin-6; D007455:Iodine; D019947:Receptors, Interleukin-6; D013954:Thyroglobulin; D000093242:Interleukin-6 Inhibitors